Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical diagnostic and treatment experience, and future directions in the discipline, creating a professional event of high academic caliber, strong clinical relevance, and significant industry influence.
Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish a high-level academic exchange platform, the 2026 Boren Precision Hematologic Oncology Conference officially opened in Beijing on May 16 in a hybrid online-offline format. The conference was jointly hosted by the Beijing Association for the Promotion of Integrated Traditional Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering.
Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:
2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

2026 CSCO BC Guideline Highlights | Professor Chunfang Hao: Key Updates in Salvage Endocrine Therapy for HR-Positive Advanced Breast Cancer — Multi-Directional Strategies, Precision Assessment, Optimized Combinations, and Sequential Multi-Target Therapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent major updates. At the meeting, Professor Chunfang Hao from Tianjin Medical University Cancer Institute and Hospital delivered a comprehensive overview of the latest advances in the management of HR-positive breast cancer.
2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

2026 CSCO Guidelines Conference | Academician Jinming Yu: Strengthening China-Based Evidence, Advancing Global Guideline Outreach, and Bringing Standardized Cancer Care to the Grassroots Level

The 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was grandly held in Harbin from April 24–25. Bringing together more than a thousand experts, the meeting focused on guideline updates, intelligent healthcare, and multidisciplinary collaboration, with a strong emphasis on extending standardized cancer care to grassroots medical institutions and narrowing regional disparities in oncology practice.
2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

2026 HOT Conference | Professor Zhenzhen Liu: From Live Surgical Demonstrations to Specialty Center Development — Advancing Breast Cancer Care on Multiple Fronts

With the warmth of spring invigorating the Central Plains, the 18th Northern Breast Cancer HOT Conference was successfully held in Zhengzhou from April 16–18, 2026. During the meeting, Oncology Frontier conducted an exclusive interview with the conference chair, Professor Zhenzhen Liu from Henan Cancer Hospital. In the interview, she discussed the conference’s major highlights, the development of specialty center models, and both the challenges and practical value of promoting multidisciplinary team (MDT) care at the grassroots level.
CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

CSCO BC 10th Anniversary Tribute | Professor Yongmei Yin: A New Starting Point, A New Mission — CSCO BC Leading China’s Breast Cancer Care into a New Era of High-Quality Development

As the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) marks its 10th anniversary, the 2026 National Breast Cancer Conference was grandly convened. More than an academic gathering, this conference served as a comprehensive review of CSCO BC’s decade-long journey and a blueprint for the future of breast cancer care in China.